The estimated Net Worth of Marco Londei is at least $2.44 million dollars as of 27 November 2019. Marco Londei owns over 46,202 units of AnaptysBio Inc stock worth over $2,441,412 and over the last 8 years Marco sold ANAB stock worth over $0.
Marco has made over 5 trades of the AnaptysBio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Marco exercised 46,202 units of ANAB stock worth $320,180 on 27 November 2019.
The largest trade Marco's ever made was exercising 142,857 units of AnaptysBio Inc stock on 7 September 2018 worth over $100,000. On average, Marco trades about 24,824 units every 45 days since 2017. As of 27 November 2019 Marco still owns at least 68,579 units of AnaptysBio Inc stock.
You can see the complete history of Marco Londei stock trades at the bottom of the page.
Marco's mailing address filed with the SEC is 10421 Pacific Center Ct, San Diego, CA 92121, USA.
Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1 et James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.
founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
AnaptysBio Inc executives and other stock owners filed with the SEC include: